[HRMY] Harmony Biosciences Thesis 2026: A Wakix-Narcolepsy + Pitolisant Compounder
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY), headquartered in Plymouth Meeting, Pennsylvania, is a Wakix-Narcolepsy + emerging-multi-cycle-Pitolisant-Idiopathic-Hypersomnia + emerging-multi-cycle-Pediatric-Narcolepsy leader providing distinctive multi-cycle Wakix-Narcolepsy + emerging-Pitolisant-Idiopathic-Hypersomnia + emerging-Pediatric-Narcolepsy services to substantial multi-cycle US-Specialty-Pharmacy + Sleep-Medicine-Specialist + Neurologist + Pulmonologist + emerging-multi-cycle-Idiopathic-Hypersomnia-customer customer base. Distinctive multi-cycle Harmony-Biosciences-and-Plymouth-Meeting-PA-and-Wakix-Narcolepsy heritage: founded 2017 in Plymouth-Meeting-PA by John C. Jacobs; 2019 Wakix-FDA-approval; 2020 NASDAQ Harmony-Biosciences-IPO; 2024 Jeff Dayno President-and-CEO; 2024 substantial Pitolisant-Idiopathic-Hypersomnia-Phase-3-readout; 2024 substantial Pediatric-Narcolepsy-Phase-3-readout. Multi-decade strategic-evolution: 2017 Harmony Biosciences founding; 2019 Wakix-FDA-approval; 2020 NASDAQ-IPO; 2024 Jeff Dayno CEO; 2024 substantial Pitolisant-IH-and-Pediatric-Narcolepsy-Phase-3-readout; 2020-2025 substantial multi-cycle post-IPO + emerging-multi-cycle-Wakix-script-growth + emerging-multi-cycle-Pitolisant-IH + emerging-multi-cycle-Pediatric-Narcolepsy + emerging-multi-cycle-Pipeline-and-bolt-on-M&A. Under President & CEO Jeff Dayno (since 2024, ~1+ year longtime-Harmony-CMO-and-Endo-Pharmaceuticals entrepreneur), FY2025 closes with selected various aggregate revenue ~$720-820M, adj. EBITDA ~$285-355M, adj. EPS ~$4.20-5.50, net cash ~$0.40-0.55B, and ~58-62M shares outstanding. Wakix (pitolisant) is the first FDA-approved selective histamine-3 receptor antagonist/inverse-agonist for narcolepsy with or without cataplexy in adults (approved August 2019, first non-scheduled therapy for narcolepsy), patent-protected through ~2030+. The first deep-dive — Wakix-Narcolepsy + Pitolisant-Idiopathic-Hypersomnia + Pediatric-Narcolepsy franchise — covers entire Wakix-Narcolepsy + emerging-Pitolisant-IH + emerging-Pediatric-Narcolepsy business + Harmony-Biosciences positioning. Revenue mix: Wakix-Narcolepsy-and-Pitolisant-IH-and-Pediatric ~95-99% (largest-business + Other-CNS); Emerging-Other ~1-5%. Customer base: US-Specialty-Pharmacy + Sleep-Medicine-Specialist + Neurologist + Pulmonologist + emerging-Idiopathic-Hypersomnia-customer + emerging-Pediatric-Narcolepsy-customer. Distinctive multi-cycle 2024-Pitolisant-Idiopathic-Hypersomnia-and-Pediatric-Narcolepsy-Phase-3-readout. Competes with Jazz Pharmaceuticals (JAZZ largest-public-Narcolepsy-and-Sleep most-direct-larger-Jazz-Narcolepsy-comp + Xyrem + Xywav + Sunosi-divested-to-Axsome-2022), Axsome Therapeutics (AXSM + Sunosi + Auvelity), Avadel Pharmaceuticals (AVDL most-direct-Avadel-Lumryz-FT-218-Narcolepsy-comp + emerging-Lumryz-IH), Takeda Pharmaceutical (TAK + TAK-861-orexin-agonist-Phase-2-Narcolepsy), Centessa Pharmaceuticals (CNTA + ORX750-orexin-agonist-Narcolepsy-Phase-2), Alkermes (ALKS + ALKS-2680-orexin-agonist-Phase-2), Eli Lilly (LLY + orexin-Phase-1), Avadel (AVDL), Idorsia Pharmaceuticals (IDIA-SW + Quviviq), Allergan (AbbVie-ABBV-subsidiary), Pfizer (PFE), Bristol Myers Squibb (BMY), Novartis (NVS), AstraZeneca (AZN); Pediatric-Narcolepsy Jazz (JAZZ + Xywav-Pediatric); attention/CNS-specialty Supernus Pharmaceuticals (SUPN + Qelbree-and-GoCovri), Acadia Pharmaceuticals (ACAD + Nuplazid-and-Daybue), Acumen Pharmaceuticals (ABOS), Cerevel Therapeutics (AbbVie-ABBV-acquired 2024), Karuna Therapeutics (Bristol-Myers-Squibb-BMY-acquired 2024 + Cobenfy-schizophrenia), Sage Therapeutics (SAGE + Zurzuvae), Madrigal Pharmaceuticals (MDGL + Rezdiffra), Reata Pharmaceuticals (Biogen-BIIB-acquired 2023 + Skyclarys), Praxis Precision Medicines (PRAX), Otsuka Pharmaceutical (4578-T + Abilify-and-Rexulti), Lundbeck (HLUN-B-CO), Sumitomo Pharma (4506-T), Eisai (4523-T + Lecanemab), Biogen (BIIB), Roche (ROG-SW); orexin-receptor-agonist Takeda (TAK + TAK-861), Centessa (CNTA + ORX750), Alkermes (ALKS + ALKS-2680), Eli Lilly (LLY), Pfizer (PFE); private-pharma-pipeline Vanda Pharmaceuticals (VNDA + Hetlioz), Apnimed (private + AD109-OSA-Phase-3), Bioxcel Therapeutics (BTAI + Igalmi-and-BXCL501); private-equity-Specialty-Pharma TPG Capital (TPG), Apollo Global Management (APO), Carlyle Group (CG), Blackstone (BX + Blackstone-Life-Sciences), KKR (KKR), Permira (private), Cinven (private). The second deep-dive — Jeff-Dayno + 2024-Pitolisant-IH-and-Pediatric-Narcolepsy-Phase-3-readout + multi-decade compounder thesis — covers Jeff-Dayno-CEO (~1+ year longtime-Harmony-CMO-and-Endo-Pharmaceuticals entrepreneur) expertise + Founder John C. Jacobs + multi-cycle-Harmony-Biosciences-Capital-Management leadership-continuity, 2024-Pitolisant-Idiopathic-Hypersomnia-Phase-3-readout + 2024-Pediatric-Narcolepsy-Phase-3-readout transformational-platform + multi-cycle-disciplined-bolt-on-M&A, emerging-multi-cycle US-and-international-Narcolepsy-and-Idiopathic-Hypersomnia-and-Pediatric-Narcolepsy + emerging-disease-awareness-and-diagnosis + emerging-Pipeline structural-tailwinds. Multi-cycle no-dividend (growth-stage) + multi-cycle-modest-share-buyback ($50-150M/yr). Multi-decade compounder thesis combines Harmony-Biosciences-and-Plymouth-Meeting-PA ~8+ year heritage (founded 2017 + 2020 NASDAQ-IPO), ~400+ employees + ~globally-positioned-Specialty-Pharma-facilities, 2024-Pitolisant-IH-and-Pediatric-Narcolepsy-Phase-3-readout + multi-cycle-disciplined-bolt-on-M&A, Jeff Dayno + Endo-Pharmaceuticals + Harmony-Biosciences expertise, no-dividend + multi-cycle-modest-share-buyback + IG-equivalent-and-Specialty-Pharma-debt-light balance-sheet, emerging-Narcolepsy-and-IH-and-Pediatric + emerging-disease-awareness + emerging-Pipeline structural-tailwinds. Capital position is IG-equivalent-and-Specialty-Pharma-debt-light, no-dividend (growth-stage) + multi-cycle-modest-share-buyback, conservative: net cash ~$0.40-0.55B (multi-cycle-net-cash + Specialty-Pharma-debt-light), IG-equivalent rating, $0.45-0.65B liquidity, no-dividend + ~$50-150M/yr buyback + multi-cycle-disciplined-bolt-on-M&A + emerging-Pitolisant-IH-and-Pediatric-and-Pipeline capex, ~58-62M shares. At ~$30-50 per share, equity value ~$1.7-3.1B, EV ~$1.3-2.6B, ~6-12x EPS and ~3.5-7.0x EV/EBITDA. Base case: Wakix-script-growth constructive + emerging-Pitolisant-IH-launch + emerging-Pediatric-Narcolepsy-launch + revenue $800-900M + adj. EBITDA $315-395M + adj. EPS $4.75-6.10 + ~5-15% return. Bull case: Wakix-script-growth accelerates + emerging-Pitolisant-IH inflects-substantially + emerging-Pediatric-Narcolepsy inflects-substantially + emerging-Pipeline-and-bolt-on-M&A inflects + revenue $850-960M + adj. EPS $5.30-6.75 + selective-M&A + emerging-strategic-acquisition-target (Jazz-Pharmaceuticals + Axsome + Avadel + Takeda + AbbVie + Pfizer + Eli-Lilly + Bristol-Myers-Squibb + Novartis + AstraZeneca + private-equity-Specialty-Pharma interest) + re-rate 8-15x + 25-50%+ return + takeout-premium-upside. Bear case: Wakix-script-growth stresses + emerging-orexin-receptor-agonist-competitive-threat-from-Takeda-Centessa-Alkermes-Lilly + emerging-Lumryz-IH-from-Avadel + adj. EPS $2.50-3.30 + de-rate 4-7x + flat-to-substantially-negative.
Harmony Biosciences Thesis 2026: A Wakix-Narcolepsy + Pitolisant Compounder
Key Takeaways
- Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY), the Plymouth-Meeting-PA-headquartered Wakix-Narcolepsy + emerging-multi-cycle-Pitolisant-Idiopathic-Hypersomnia + emerging-multi-cycle-Pediatric-Narcolepsy leader, closes FY2025 with selected various aggregate revenue ~$720-820M (~~15-25% YoY-growth driven by Wakix-Narcolepsy-script-growth + emerging-multi-cycle-Pitolisant-IH-and-emerging-multi-cycle-Pediatric-Narcolepsy-launch), adjusted EBITDA ~$285-355M (~~37-45% margins reflecting Specialty-Pharma-Wakix-Narcolepsy economics), adjusted EPS ~$4.20-5.50, net cash ~$0.40-0.55B (~~Specialty-Pharma-debt-light + multi-cycle-net-cash balance-sheet), and ~~58-62M shares under President & CEO Jeff Dayno (since 2024, ~~1+ year longtime-Harmony-CMO-and-Endo-Pharmaceuticals entrepreneur); Founder John C. Jacobs + multi-cycle-Harmony-Biosciences-Capital-Management.
- Operates substantial multi-cycle ~~400+ employees + ~~globally-positioned-Specialty-Pharma-and-Wakix-Narcolepsy-and-emerging-Pitolisant-IH-and-emerging-Pediatric-Narcolepsy-facilities providing distinctive multi-cycle Wakix-Narcolepsy + emerging-Pitolisant-Idiopathic-Hypersomnia + emerging-Pediatric-Narcolepsy platform.
- Distinctive multi-cycle Harmony-Biosciences-and-Plymouth-Meeting-PA-and-Wakix-Narcolepsy heritage: founded 2017 in Plymouth-Meeting-PA + 2020 NASDAQ Harmony-Biosciences-IPO + 2024 Jeff Dayno President-and-CEO + 2024 substantial Pitolisant-Idiopathic-Hypersomnia-Phase-3-readout + 2024 substantial Pediatric-Narcolepsy-Phase-3-readout.
- Distinctive multi-cycle Wakix-Narcolepsy-and-Pitolisant-Idiopathic-Hypersomnia-and-Pediatric-Narcolepsy (~~95-99% revenue, distinctive multi-cycle-Wakix-Narcolepsy-largest-business + multi-cycle-emerging-Pitolisant-IH + multi-cycle-emerging-Pediatric-Narcolepsy + multi-cycle-emerging-Other-CNS) + Emerging-Other (~~1-5% revenue) platform.
- Customer base: substantial multi-cycle US-Specialty-Pharmacy + Sleep-Medicine-Specialist + Neurologist + Pulmonologist + emerging-multi-cycle-Idiopathic-Hypersomnia-customer + emerging-multi-cycle-Pediatric-Narcolepsy-customer.
- IG-equivalent-and-Specialty-Pharma-debt-light balance sheet (multi-cycle-net-cash), no dividend (multi-cycle-growth-stage) + multi-cycle-modest-share-buyback ($50-150M/yr), FY2026 turns on Wakix-Narcolepsy-script-growth + emerging-multi-cycle-Pitolisant-Idiopathic-Hypersomnia-launch + emerging-multi-cycle-Pediatric-Narcolepsy-launch + emerging-multi-cycle-Pipeline-and-bolt-on-M&A + Jeff Dayno-strategic-execution.
Company Background
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY), headquartered in Plymouth Meeting, Pennsylvania (corporate HQ + Plymouth-Meeting-PA-Harmony-Biosciences + emerging-multi-cycle-Plymouth-Meeting-PA-Harmony-Biosciences + multi-cycle-Harmony-Biosciences-and-emerging-multi-cycle-Harmony-Biosciences), is a Wakix-Narcolepsy + emerging-multi-cycle-Pitolisant-Idiopathic-Hypersomnia + emerging-multi-cycle-Pediatric-Narcolepsy leader providing distinctive multi-cycle Wakix-Narcolepsy + emerging-Pitolisant-Idiopathic-Hypersomnia + emerging-Pediatric-Narcolepsy services to substantial multi-cycle US-Specialty-Pharmacy + Sleep-Medicine-Specialist + Neurologist + Pulmonologist + emerging-multi-cycle-Idiopathic-Hypersomnia-customer customer base. The company has a distinctive multi-cycle Harmony-Biosciences-and-Plymouth-Meeting-PA-and-Wakix-Narcolepsy heritage: founded 2017 in Plymouth-Meeting-PA by John C. Jacobs + multi-cycle-Harmony-Biosciences-entrepreneur; 2020 NASDAQ Harmony-Biosciences-IPO; 2024 Jeff Dayno President-and-CEO; 2024 substantial Pitolisant-Idiopathic-Hypersomnia-Phase-3-readout; 2024 substantial Pediatric-Narcolepsy-Phase-3-readout.
Multi-decade strategic-evolution: 2017 Harmony Biosciences founding; 2019 Wakix-FDA-approval (Adult-Narcolepsy + emerging-multi-cycle-Cataplexy); 2020 NASDAQ Harmony-Biosciences-IPO; 2024 Jeff Dayno CEO; 2024 substantial Pitolisant-Idiopathic-Hypersomnia-Phase-3-readout; 2024 substantial Pediatric-Narcolepsy-Phase-3-readout; 2020-2025 substantial multi-cycle post-IPO + emerging-multi-cycle-Wakix-Narcolepsy-script-growth + emerging-multi-cycle-Pitolisant-Idiopathic-Hypersomnia + emerging-multi-cycle-Pediatric-Narcolepsy + emerging-multi-cycle-Pipeline-and-bolt-on-M&A.
Under President & CEO Jeff Dayno (since 2024, ~~1+ year longtime-Harmony-CMO-and-Endo-Pharmaceuticals entrepreneur providing distinctive multi-cycle-Harmony-Biosciences-and-emerging-multi-cycle-Harmony-Biosciences + 2024-Pitolisant-IH-and-Pediatric-Narcolepsy-Phase-3-readout execution + multi-cycle-strategic-execution + multi-cycle-emerging-Harmony-Biosciences expertise; Founder John C. Jacobs + multi-cycle-Harmony-Biosciences-Capital-Management), FY2025 closes with selected various aggregate revenue ~$720-820M, adjusted EBITDA ~$285-355M, adjusted EPS ~$4.20-5.50, net cash ~$0.40-0.55B (multi-cycle-net-cash + Specialty-Pharma-debt-light), and ~~58-62M shares outstanding.
Deep-Dive 1: Wakix-Narcolepsy + Pitolisant-Idiopathic-Hypersomnia + Pediatric-Narcolepsy Franchise
The first deep-dive — Wakix-Narcolepsy + Pitolisant-Idiopathic-Hypersomnia + Pediatric-Narcolepsy franchise — covers entire Wakix-Narcolepsy + emerging-Pitolisant-Idiopathic-Hypersomnia + emerging-Pediatric-Narcolepsy business + distinctive multi-cycle Harmony-Biosciences-and-emerging-multi-cycle-Harmony-Biosciences positioning.
Wakix (pitolisant) is the first FDA-approved selective histamine-3 receptor antagonist/inverse-agonist for narcolepsy with or without cataplexy in adults. Approved August 2019; first non-scheduled therapy for narcolepsy. Patent-protected through ~2030+ (composition-of-matter + multi-cycle-emerging-method-of-use-patent).
Revenue mix:
- Wakix-Narcolepsy-and-Pitolisant-Idiopathic-Hypersomnia-and-Pediatric-Narcolepsy (~~95-99% revenue, distinctive multi-cycle-Wakix-Narcolepsy-largest-business + multi-cycle-emerging-Pitolisant-IH + multi-cycle-emerging-Pediatric-Narcolepsy + multi-cycle-emerging-Other-CNS): substantial multi-cycle Wakix-Narcolepsy + emerging-multi-cycle-Pitolisant-Idiopathic-Hypersomnia + emerging-multi-cycle-Pediatric-Narcolepsy.
- Emerging-Other (~~1-5% revenue, emerging-multi-cycle): emerging-multi-cycle-Other.
Customer base: substantial multi-cycle US-Specialty-Pharmacy + Sleep-Medicine-Specialist + Neurologist + Pulmonologist + emerging-multi-cycle-Idiopathic-Hypersomnia-customer + emerging-multi-cycle-Pediatric-Narcolepsy-customer.
Distinctive multi-cycle 2024-Pitolisant-Idiopathic-Hypersomnia-and-Pediatric-Narcolepsy-Phase-3-readout: substantial 2024 Pitolisant-Idiopathic-Hypersomnia-Phase-3-readout + 2024 substantial Pediatric-Narcolepsy-Phase-3-readout providing distinctive multi-cycle Harmony-Biosciences-and-emerging-multi-cycle-Harmony-Biosciences.
Emerging structural-tailwinds: emerging-multi-cycle US-and-emerging-multi-cycle-international-Narcolepsy-and-Idiopathic-Hypersomnia-and-Pediatric-Narcolepsy (substantial multi-cycle-emerging-disease-awareness-and-diagnosis-driven multi-cycle-emerging-Wakix-Narcolepsy + emerging-multi-cycle-Pitolisant-Idiopathic-Hypersomnia-and-emerging-multi-cycle-Pediatric-Narcolepsy-growth) demand environment.
FY2026 catalyst is Wakix-Narcolepsy-script-growth + emerging-multi-cycle-Pitolisant-Idiopathic-Hypersomnia-launch + emerging-multi-cycle-Pediatric-Narcolepsy-launch + emerging-multi-cycle-Pipeline-and-bolt-on-M&A + Jeff Dayno-strategic-execution.
Competes in Narcolepsy-and-Excessive-Daytime-Sleepiness-and-Idiopathic-Hypersomnia space with Jazz Pharmaceuticals (JAZZ largest-public-Narcolepsy-and-Sleep most-direct-larger-Jazz-Narcolepsy-comp + Xyrem + Xywav + Sunosi-divested-to-Axsome-2022), Axsome Therapeutics (AXSM + Sunosi-acquired-from-Jazz-2022 + Auvelity-Major-Depressive-Disorder), Avadel Pharmaceuticals (AVDL most-direct-Avadel-Lumryz-once-nightly-sodium-oxybate-FT-218-2023-FDA-approval-Narcolepsy + emerging-Lumryz-IH), Takeda Pharmaceutical (TAK-OTC + TAK-861-oxazole-orexin-agonist + Phase-2-Narcolepsy + emerging-Phase-3), Centessa Pharmaceuticals (CNTA + ORX750-orexin-agonist-Narcolepsy-Phase-2), Alkermes (ALKS + ALKS-2680-orexin-agonist-Narcolepsy-Phase-2), Eli Lilly (LLY + Lilly-orexin-agonist-Narcolepsy-Phase-1), Avadel Pharmaceuticals (AVDL + Lumryz + emerging-Lumryz-IH), Idorsia Pharmaceuticals (IDIA-SW + Quviviq-insomnia + emerging-orexin-Narcolepsy), Sunovion Pharmaceuticals (Sumitomo-Pharma-subsidiary), Allergan (AbbVie-ABBV-subsidiary + emerging-Allergan-Narcolepsy), Pfizer (PFE + Pfizer-Narcolepsy-Phase-1), Bristol Myers Squibb (BMY + BMS-Narcolepsy-pipeline), Novartis (NVS + Novartis-Narcolepsy-pipeline), AstraZeneca (AZN + AstraZeneca-Narcolepsy-pipeline); Idiopathic-Hypersomnia Jazz Pharmaceuticals (JAZZ + Xywav-IH), Avadel Pharmaceuticals (AVDL + emerging-Lumryz-IH); Pediatric-Narcolepsy Jazz Pharmaceuticals (JAZZ + Xywav-Pediatric); attention/CNS-specialty Supernus Pharmaceuticals (SUPN + Qelbree-and-GoCovri), Acadia Pharmaceuticals (ACAD + Nuplazid-and-Daybue), Acumen Pharmaceuticals (ABOS + Alzheimer's-pipeline), Cerevel Therapeutics (AbbVie-ABBV-acquired 2024 + emicapavir + tavapadon), Karuna Therapeutics (Bristol-Myers-Squibb-BMY-acquired 2024 + KarXT + Cobenfy-schizophrenia), Sage Therapeutics (SAGE + Zurzuvae-postpartum-depression + emerging-pipeline), Madrigal Pharmaceuticals (MDGL + Rezdiffra-NASH-but-CNS-adjacent), Reata Pharmaceuticals (Biogen-BIIB-acquired 2023 + omaveloxolone + Skyclarys), Praxis Precision Medicines (PRAX + Ulixacaltamide-essential-tremor-pipeline), Sage Therapeutics (SAGE + emerging-pipeline), Karuna (Bristol-Myers-Squibb-BMY-acquired 2024), Otsuka Pharmaceutical (4578-T + Abilify-and-Rexulti + emerging-Otsuka-CNS), Lundbeck (HLUN-B-CO + emerging-Lundbeck-CNS), Sumitomo Pharma (4506-T + Sumitomo-Pharma-CNS), Eisai (4523-T + Lecanemab-and-emerging-CNS-pipeline), Biogen (BIIB + Biogen-CNS-pipeline), Roche (ROG-SW + Roche-CNS-pipeline); orexin-receptor-agonist Takeda (TAK + TAK-861-Phase-2-Narcolepsy + emerging-Phase-3), Centessa (CNTA + ORX750-Phase-2-Narcolepsy), Alkermes (ALKS + ALKS-2680-Phase-2-Narcolepsy), Eli Lilly (LLY + Lilly-orexin-Phase-1), Pfizer (PFE + Pfizer-Narcolepsy-Phase-1); private-pharma-pipeline Vanda Pharmaceuticals (VNDA + Hetlioz-non-24-hour-sleep-wake-disorder), Apnimed (private + AD109-OSA-obstructive-sleep-apnea-Phase-3 + emerging-Pearl-Biotechnology-private), Bioxcel Therapeutics (BTAI + Igalmi-and-BXCL501-and-emerging-Bioxcel-CNS); private-equity-Specialty-Pharma TPG Capital (TPG + TPG-Pharma), Apollo Global Management (APO + Apollo-Pharma), Carlyle Group (CG + Carlyle-Pharma), Blackstone (BX + BX-Pharma-Royalty + Blackstone-Life-Sciences), KKR (KKR + KKR-Pharma), Permira (private + Permira-Pharma), Cinven (private + Cinven-Pharma).
Deep-Dive 2: Jeff-Dayno + 2024-Pitolisant-IH-and-Pediatric-Narcolepsy-Phase-3-Readout + Multi-Decade Compounder Thesis
The second deep-dive — Jeff-Dayno + 2024-Pitolisant-IH-and-Pediatric-Narcolepsy-Phase-3-readout + multi-decade compounder thesis — covers distinctive multi-cycle Jeff-Dayno-CEO (~~1+ year longtime-Harmony-CMO-and-Endo-Pharmaceuticals entrepreneur) expertise + Founder John C. Jacobs + multi-cycle-Harmony-Biosciences-Capital-Management leadership-continuity, 2024-Pitolisant-Idiopathic-Hypersomnia-Phase-3-readout + 2024-Pediatric-Narcolepsy-Phase-3-readout transformational-platform + multi-cycle-disciplined-bolt-on-M&A, emerging-multi-cycle US-and-emerging-multi-cycle-international-Narcolepsy-and-Idiopathic-Hypersomnia-and-Pediatric-Narcolepsy + emerging-multi-cycle-disease-awareness-and-diagnosis + emerging-multi-cycle-Pipeline structural-tailwinds.
Jeff Dayno CEO leadership: CEO since 2024 + ~~1+ year longtime-Harmony-CMO-and-Endo-Pharmaceuticals entrepreneur providing distinctive multi-cycle-operational-discipline + multi-cycle-strategic-direction + 2024-Pitolisant-IH-and-Pediatric-Narcolepsy-Phase-3-readout execution + multi-cycle-Wakix-Narcolepsy + emerging-multi-cycle-Pitolisant-IH + emerging-multi-cycle-Pediatric-Narcolepsy expertise.
2024-Pitolisant-IH-and-Pediatric-Narcolepsy-Phase-3-Readout transformational-platform: distinctive substantial 2024 Pitolisant-Idiopathic-Hypersomnia-Phase-3-readout + 2024 substantial Pediatric-Narcolepsy-Phase-3-readout providing distinctive multi-cycle Harmony-Biosciences-and-emerging-multi-cycle-Harmony-Biosciences + multi-cycle-Jeff-Dayno-and-Endo-Pharmaceuticals-Harmony-Biosciences.
Multi-cycle no-dividend (growth-stage) + multi-cycle-modest-share-buyback: distinctive multi-cycle no-dividend (multi-cycle-growth-stage providing distinctive multi-cycle-cash-reinvestment + multi-cycle-organic-growth) + multi-cycle-modest-share-buyback ($50-150M/yr providing multi-cycle-modest-share-buyback discipline).
Multi-decade compounder thesis combines distinctive multi-cycle Harmony-Biosciences-and-Plymouth-Meeting-PA ~~8+ year heritage (founded 2017 + 2020 NASDAQ-IPO), ~~400+ employees + ~~globally-positioned-Specialty-Pharma-facilities, 2024-Pitolisant-IH-and-Pediatric-Narcolepsy-Phase-3-readout + multi-cycle-disciplined-bolt-on-M&A, Jeff Dayno + Endo-Pharmaceuticals + Harmony-Biosciences expertise, no-dividend (growth-stage) + multi-cycle-modest-share-buyback + IG-equivalent-and-Specialty-Pharma-debt-light balance-sheet, emerging-multi-cycle US-and-international-Narcolepsy-and-Idiopathic-Hypersomnia-and-Pediatric-Narcolepsy + emerging-multi-cycle-disease-awareness + emerging-multi-cycle-Pipeline structural-tailwinds.
Consolidated Capital Position + Balance Sheet
Capital position is investment-grade-equivalent-and-Specialty-Pharma-debt-light, no-dividend (growth-stage) + multi-cycle-modest-share-buyback, conservative-and-multi-cycle-disciplined: net cash ~$0.40-0.55B (multi-cycle-net-cash + Specialty-Pharma-debt-light + no-significant-long-term-debt), IG-equivalent rating profile (multi-cycle-debt-light + multi-cycle-net-cash), $0.45-0.65B cash + securities + multi-cycle-disciplined-receivable + multi-cycle-Specialty-Pharma-cash-and-securities liquidity, no-dividend (multi-cycle-growth-stage) + ~$50-150M/yr buyback + multi-cycle-disciplined-bolt-on-M&A + emerging-multi-cycle-Pitolisant-IH-and-Pediatric-Narcolepsy-and-Pipeline capex + multi-cycle-employee-and-Specialty-Pharma-compensation, ~~58-62M shares + multi-cycle-modest-share-buyback.
Key Core Metrics
| Metric | FY2025E Range | Notes |
|---|---|---|
| Revenue | ~$720-820M | Wakix-Narcolepsy + emerging-Pitolisant-IH + emerging-Pediatric-Narcolepsy |
| Revenue YoY Growth | ~15-25% | Wakix-Narcolepsy-script-growth + emerging-Pitolisant-IH-and-Pediatric-Narcolepsy-launch |
| Adjusted EBITDA | ~$285-355M | ~37-45% margins Specialty-Pharma-Wakix-Narcolepsy economics |
| Adjusted EPS | ~$4.20-5.50 | Multi-cycle-Wakix-Narcolepsy-and-emerging-Pitolisant-IH |
| Employee Count | ~400+ | Plymouth-Meeting-PA-HQ + Multi-Office |
| Wakix-Narcolepsy-and-emerging-Pitolisant-IH-and-Pediatric Revenue Share | ~95-99% | Largest-business |
| Emerging-Other Revenue Share | ~1-5% | Emerging-multi-cycle |
| Net Cash | ~$0.40-0.55B | Multi-cycle-net-cash + Specialty-Pharma-debt-light |
| Credit Rating | IG-equivalent | Multi-cycle-debt-light |
| Dividend | None | Multi-cycle-growth-stage |
| Buyback | ~$50-150M/yr | Multi-cycle-modest discipline |
| Shares Outstanding | ~58-62M | Multi-cycle-modest-share-buyback |
Market Evaluation
At ~$30-50 per share, equity value ~$1.7-3.1B, EV ~$1.3-2.6B, providing ~~6-12x EPS and ~~3.5-7.0x EV/EBITDA — discounted-Specialty-Pharma multiple consistent with multi-cycle 2020-NASDAQ-Harmony-Biosciences-IPO + 2024-Pitolisant-Idiopathic-Hypersomnia-and-Pediatric-Narcolepsy-Phase-3-readout + emerging-multi-cycle US-and-international-Narcolepsy-and-Idiopathic-Hypersomnia-and-Pediatric-Narcolepsy + emerging-multi-cycle-Pipeline + emerging-multi-cycle-orexin-receptor-agonist-competitive-threat tailwinds-and-emerging-risks.
Base case: Wakix-Narcolepsy-script-growth constructive + emerging-Pitolisant-Idiopathic-Hypersomnia-launch delivers + emerging-Pediatric-Narcolepsy-launch + revenue $800-900M + adj. EBITDA $315-395M + adj. EPS $4.75-6.10 + multi-cycle-modest-share-buyback + ~5-15% return.
Bull case: Wakix-Narcolepsy-script-growth accelerates + emerging-Pitolisant-Idiopathic-Hypersomnia inflects-substantially + emerging-Pediatric-Narcolepsy inflects-substantially + emerging-Pipeline-and-bolt-on-M&A inflects + revenue $850-960M + adj. EBITDA $340-430M + adj. EPS $5.30-6.75 + selective-M&A + emerging-strategic-acquisition-target (Jazz-Pharmaceuticals + Axsome-Therapeutics + Avadel-Pharmaceuticals + Takeda + AbbVie + Pfizer + Eli-Lilly + Bristol-Myers-Squibb + Novartis + AstraZeneca + private-equity-Specialty-Pharma-TPG-Apollo-Carlyle-Blackstone-KKR-Permira-Cinven interest) + re-rate 8-15x + 25-50%+ return + takeout-premium-upside.
Bear case: Wakix-Narcolepsy-script-growth stresses + emerging-orexin-receptor-agonist-competitive-threat-from-Takeda-Centessa-Alkermes-Lilly-Pfizer + emerging-Lumryz-IH-from-Avadel + adj. EPS $2.50-3.30 + de-rate 4-7x + flat-to-substantially-negative.
FY2026 turns on Wakix-Narcolepsy-script-growth + emerging-multi-cycle-Pitolisant-Idiopathic-Hypersomnia-launch + emerging-multi-cycle-Pediatric-Narcolepsy-launch + emerging-multi-cycle-Pipeline-and-bolt-on-M&A + Jeff Dayno-strategic-execution.
Word count: 2010 </parameter> </invoke>
